Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat Drug-Drug Interaction Study with Midazolam, Digoxin, Rosuvastatin, Pitavastatin, and Metformin
NCT06813924Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of etavopivat in sickle cell disease (SCD) and thalassemia (5 arms), sponsored by Novo Nordisk. Primary endpoints: Maximum observed plasma concentration at Day 3 and Area under the plasma concentration-time curve from 0 hours to infinity at Day 3. Started Feb 2025; status: completed.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT06813924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813924.